Adverse effects of antiretroviral therapy for HIV infection.
暂无分享,去创建一个
J. Montaner | M. Harris | Julio S G Montaner | Marianne Harris | Valentina Montessori | Natasha Press | Linda Akagi | N. Press | V. Montessori | L. Akagi
[1] R. Hewitt. Abacavir hypersensitivity reaction. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] T. Hassanein,et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] D. Johns. The other human genome: Mitochondrial DNA and disease , 1996, Nature Medicine.
[4] W. K. Henry,et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] J. Montaner,et al. Anaerobic threshold and random venous lactate levels among HIV-positive patients on antiretroviral therapy. , 2002, Journal of acquired immune deficiency syndromes.
[6] M. Moroni,et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.
[7] A. Schwenk,et al. Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study. , 2000, European journal of medical research.
[8] A Muñoz,et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.
[9] D. Skiest,et al. Osteonecrosis in HIV: A Case‐Control Study , 2000, Journal of acquired immune deficiency syndromes.
[10] S. Kukich. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000. , 2001, MMWR. Morbidity and mortality weekly report.
[11] R. Narins,et al. Clinical use of the anion gap. , 1977, Medicine.
[12] L. Roudière,et al. Osteonecrosis of the hip, lipodystrophy and antiretroviral treatment. , 2000, AIDS.
[13] J. Frohlich,et al. Common problems in the management of hypertriglyceridemia. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[14] L. Naldi,et al. Nevirapine and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis , 2001, AIDS.
[15] P. Gabow,et al. Diagnostic importance of an increased serum anion gap. , 1980, The New England journal of medicine.
[16] J. Olano,et al. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] C. Shikuma,et al. Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS. , 1999, AIDS.
[18] P. Gabow,et al. The fall of the serum anion gap. , 1990, Archives of internal medicine.
[19] R. Garry,et al. Both necrosis and apoptosis contribute to HIV-1-induced killing of CD4 cells. , 1999, AIDS.
[20] R. Hogg,et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[21] E. Zafrani,et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. , 1999, Journal of hepatology.
[22] I. G. Fantus,et al. New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[23] K. K. Lai,et al. Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI). , 1991, Annals of internal medicine.
[24] D. Dieterich. Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. , 1999, The American journal of medicine.
[25] Lenzo Np,et al. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. , 1997 .
[26] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[27] M. Dubé. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] L. Ostrosky-Zeichner,et al. Liposuction for protease-inhibitor-associated lipodystrophy. , 1999, The Lancet.
[29] R. Luzzati,et al. Riboflavine and severe lactic acidosis , 1999, The Lancet.
[30] R. Chaisson,et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.
[31] J. L. Martin,et al. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis , 1994, Antimicrobial Agents and Chemotherapy.
[32] Ignacio Conget,et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study , 2001, The Lancet.
[33] R. Chaisson,et al. Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.
[34] C. Schramm,et al. Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis. , 1999, European journal of anaesthesiology.
[35] R. Chaisson,et al. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. , 1995, The American journal of gastroenterology.
[36] S. Pahwa,et al. Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac. , 2001, AIDS patient care and STDs.
[37] Jacques P. Brown,et al. The 2002 Canadian bone densitometry recommendations: take-home messages. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[38] D. Cooper,et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance , 1998, The Lancet.
[39] P. Matthews,et al. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease , 1993, Neurology.
[40] H. Przyrembel,et al. Therapy of mitochondrial disorders , 1987, Journal of Inherited Metabolic Disease.
[41] T. Antoniou,et al. Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[42] M. Chevallier,et al. Fulminant hepatitis with severe lactate acidosis in HIV‐infected patients on didanosine therapy , 1994, Journal of internal medicine.
[43] A. Koeger,et al. Multiple site avascular necrosis in HIV infected patients. , 1991, The Journal of rheumatology.
[44] D. Cooper,et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome , 2000, AIDS.
[45] J. Smeitink,et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway , 1998, AIDS.
[46] J. Shapiro,et al. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. , 1997, Critical care medicine.
[47] D. Cooper,et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.
[48] L. Ostrosky-Zeichner,et al. Liposuction for protease-inhibitorassociated lipodystrophy , 1999, The Lancet.
[49] C. Moore,et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy , 2001, AIDS.
[50] D. Cooper,et al. Adverse effects of antiretroviral therapy , 2000, The Lancet.
[51] M. Dalakas,et al. Mitochondrial toxicity of antiviral drugs , 1995, Nature Medicine.
[52] C. Tsai,et al. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides , 1994, Antimicrobial Agents and Chemotherapy.
[53] S. Dimauro,et al. Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. , 2001, The Journal of pediatrics.
[54] V. Soriano,et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy , 2000, AIDS.
[55] P. Gabow. Disorders associated with an altered anion gap. , 1985, Kidney international.
[56] C. Katlama,et al. Factors affecting liver fibrosis in human immunodeficiency virus–and hepatitis C virus–coinfected patients: Impact of protease inhibitor therapy , 2001, Hepatology.
[57] Jacques P. Brown,et al. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[58] Mark Dybul,et al. Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV* , 2002, Annals of Internal Medicine.
[59] R. Reves,et al. Riboflavin to treat nucleoside analogue-induced lactic acidosis , 1998, The Lancet.
[60] P. Clay. The abacavir hypersensitivity reaction: a review. , 2002, Clinical therapeutics.
[61] K. Yarasheski,et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy , 2000, AIDS.
[62] N. Paton,et al. Bone Mineral Density in Patients with Human Immunodeficiency Virus Infection , 1997, Calcified Tissue International.
[63] J. Frohlich,et al. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[64] O. Rouvière,et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. , 1999, AIDS.
[65] K. Brinkman,et al. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. , 2000, AIDS.
[66] J. Montaner,et al. Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[67] P. Giangrande,et al. Increased bleeding associated with protease inhibitor therapy in HIV‐positive patients with bleeding disorders , 1999, British journal of haematology.
[68] David A. Cooper,et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.
[69] J. Arenas,et al. Plasma carnitine insufficiency and effectiveness of L‐carnitine therapy in patients with mitochondril myopathy , 1993, Muscle & nerve.
[70] P. Reiss,et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection , 2000, AIDS.
[71] P. Harrigan,et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. , 2002, The New England journal of medicine.